Related Experiment Videos
Synthesis of antiprogestational steroids
1Research Laboratories, Schering AG, Berlin, F.R.G.
Journal of Steroid Biochemistry
|January 1, 1987
Summary
Researchers are developing new anti-progestin drugs, like RU 38,486, ZK 98,734, and ZK 98,299, which show varying potencies and behaviors in animal models for potential therapeutic use.
Area of Science:
- Pharmacology
- Medicinal Chemistry
- Endocrinology
Background:
- The discovery of the progesterone antagonist RU 38,486 spurred the search for improved anti-progestins.
- Several hundred compounds have been investigated for their anti-progestin activity.
Purpose of the Study:
- To characterize the biological activity of advanced anti-progestin derivatives.
- To compare the potency and in vivo behavior of RU 38,486, ZK 98,734, and ZK 98,299.
- To highlight synthetic challenges in creating sterically hindered steroid derivatives.
Main Methods:
- Preliminary biological screening of anti-progestin compounds.
- Detailed biological characterization of selected derivatives (RU 38,486, ZK 98,734, ZK 98,299).
- Evaluation of compound behavior in various animal models.
- Analysis of synthetic routes and challenges.
Main Results:
- RU 38,486, ZK 98,734, and ZK 98,299 exhibit distinct relative potencies.
- These compounds display different pharmacological profiles in animal models.
- The synthesis of sterically demanding structures like RU 38,486 and ZK 98,299 presents significant chemical challenges.
Conclusions:
- The characterized anti-progestins (RU 38,486, ZK 98,734, ZK 98,299) offer diverse pharmacological properties.
- Further research into these compounds may lead to novel therapeutic agents.
- Overcoming synthetic hurdles is crucial for the development of advanced anti-progestin drugs.